Semaglutide
Tier A — Act nowSemaglutide · all drugs expiring in 2031 →
Targets：GLP1R
Brand：Ozempic, Rybelsus, Wegovy
Indications (approved)：Overweight, Obesity, Type 2 diabetes, Cardiac and vascular disorders
Regional status
Factories producing this API7
Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.
7 producing factories on file — sign in to view the named list (factory details are not shown to guests).
Sign in to view factories →Synthetic routes & intermediates
Also available in our peptide catalogue
Frequently asked questions
What are the approved indications of Semaglutide?
Approved indications include: Overweight, Obesity, Type 2 diabetes, Cardiac and vascular disorders.
When does the Semaglutide patent expire?
Based on public sources, the Semaglutide patent expires in 2031.
How do I get a quote for Semaglutide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29